Later stage hospital studies of HCQ are irrelevant to HCQ's early stage efficacy

[admin]

Later stage COVID-19 hospital "studies" of hydroxychloroquine are irrelevant and reflect absolutely nothing about it's early stage efficacy. Not only that, they generally study it in a vacuum, without adding zinc (all important) and azythromycin.

Yet HCQ has repeatedly been found by treating physicians to be up to 99+% effective when used upon presentation of symptoms in combination with zinc and azythromycin (Z-pack).

Is there only one early stage outpatient study in the U.S. that uses HCQ+AZ+Zinc?
https://www.covid-19forum.org/index.php?topic=53.0

We are still searching for study of hospitalized patients in serious condition, that compares a Remdesivir group to hydroxychloroquine+zinc+azythromycin.
It would be most appreciated if forum onlookers could provide us with one.
Why hasn't there been one done to date? Since Remdesivir does not result in a statistically significant reduction in death what would there be to loose in trying (besides the obscene profits that Remdesivir is enjoying)?
___________________________

Added later:

According to Dr. Harvey Risch, professor of epidemiology at the Yale School of Public Health:  "Early outpatient illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone - or of hydroxychloroquine+azithromycin in inpatients - is irrelevant concerning efficacy of the pair in early high-risk outpatient disease. Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%, 9/100,000 users, compared to the 10,000 Americans now dying each week. These medications need to be widely available and promoted immediately for physicians to prescribe." (this was spiked by the media)
https://www.covid-19forum.org/index.php?topic=169.0
By way of comparison a 15% mortality rate among elderly and high-risk patients equates to a 15,000/100,000 chance of mortality from untreated COVID-19, compared to a 9/100,000 chance of arrhythmia related mortality from HCQ+AZ among a similar group. Dr. Risch and Dr. Zelenko also suggest Doxycycline may sometimes be used in place of Azithromycin if there are concerns.